The endocannabinoid system (ECS) is composed of two G protein-coupled receptors
(GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid …

Throughout the brain, postsynaptic neurons release substances from their cell bodies and
dendrites that regulate the strength of the synapses they receive. Diverse chemical …

Several recent findings suggest that targeting the endogenous cannabinoid system can be
considered as a potential therapeutic approach to treat Alzheimer's disease (AD). The …

Huntington's disease (HD) is a neurodegenerative disease for which there is no curative
treatment available. Given that the endocannabinoid system is involved in the pathogenesis …

Different plant-derived and synthetic cannabinoids have shown to be neuroprotective in
experimental models of Huntington's disease (HD) through cannabinoid receptor-dependent …

Endocannabinoids act as neuromodulatory and neuroprotective cues by engaging type 1
cannabinoid receptors. These receptors are highly abundant in the basal ganglia and play a …

Modulation of type 1 cannabinoid receptor (CB 1) activity has been touted as a potential
means of treating addiction, anxiety, depression, and neurodegeneration. Different agonists …

The role of endocannabinoids as inhibitory retrograde transmitters is now widely known and
intensively studied. However, endocannabinoids also influence neuronal activity by exerting …

The CB 1 cannabinoid receptor, the main molecular target of endocannabinoids and
cannabis active components, is the most abundant G protein-coupled receptor in the …

There is evidence that cannabinoid‐based medicines that are selective for different targets
in the cannabinoid signalling system (eg receptors, inactivation mechanism, enzymes) might …